Drug Profile
Alvocidib companion diagnostic - Eutropics/Sumitomo Pharma America
Alternative Names: Praedicare DxTMLatest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Eutropics Pharmaceuticals
- Developer Eutropics Pharmaceuticals; Sumitomo Pharma America; Tolero Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma Oncology is now called Sumitomo Pharma Oncology
- 28 Jan 2021 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes(Diagnosis) in USA
- 01 Jul 2020 Boston Biomedical has merged with Tolero Pharmaceuticals to form Sumitomo Dainippon Pharma Oncology